Podcasts about UC

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

En la edición de Los Tenores de este jueves 17 de julio, nuestros panelistas anticiparon el compromiso de la Universidad de Chile ante Guaraní por los playoffs de la Copa Sudamericana y una posible venta de Matías Sepúlveda al fútbol brasileño. Leandro Burgueño, Cristian Arcos, Danilo Díaz, Andrés Fernández y Víctor Cruces analizaron el presente de Colo Colo, donde Víctor Felipe Méndez habló en conferencia de prensa y se enteraron de la compleja situación de Cristián Zavala en el club. Además, comentaron la polémica nueva propiedad de O’Higgins de Rancagua, las declaraciones del entrenador de la UC, Daniel Garnero, y los nuevos avances del Claro Arena. Revive la edición de Los Tenores de este jueves 17 de julio y no te pierdas ningún detalle del “clásico de las dos”.See omnystudio.com/listener for privacy information.

Send us a textKimberly LaRose's journey from a nine-year diagnostic odyssey to creating an award-winning vodka demonstrates the remarkable resilience found in the IBD community. After struggling with unexplained symptoms that doctors repeatedly misdiagnosed, Kimberly finally received her Crohn's disease diagnosis and discovered that gluten and corn were major inflammation triggers for her body.Rather than seeing her dietary restrictions as limitations, Kimberly embraced a philosophy of "replacing, not removing." This positive mindset would prove transformative when she attended an event where she couldn't eat or drink anything due to her restrictions. What began as a half-joking call to a friend about creating their own vodka evolved into Wisher Vodka – a sugar beet-based spirit that's gluten-free, grain-free, and vegan.The path from concept to award-winning product wasn't simple. Kimberly and her co-founder Emily researched 300 distillers, visited 60 personally, and developed a unique production process that includes lab testing every batch to ensure purity. Their commitment to quality and transparency has earned them multiple prestigious awards, including Grand Vodka of the Year with a remarkable 98-point taste rating from the Bartender Spirits Award.Beyond the business success, Kimberly's story highlights how health challenges can unexpectedly open new doors. "I wouldn't have created Wisher had I not been diagnosed with Crohn's," she reflects. Her work supporting the Crohn's and Colitis Foundation further demonstrates her commitment to the IBD community that sparked her entrepreneurial journey.Whether you're navigating dietary restrictions, seeking inspiration for managing chronic illness, or simply appreciate the story behind your spirits, Kimberly's journey reminds us that sometimes our greatest struggles lead to our most meaningful creations. Links: Sip with Confidence! - Wisher Vodka's websiteCocktail recipesLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

A UC researcher says they're getting closer — if they can secure funding to continue.

In this episode, Tina shares four key insights she wishes she knew when first diagnosed with ulcerative colitis 14 years ago. Tina emphasizes that dietary changes can be hit-or-miss, not all about food, and sometimes medication is necessary despite initial fears. She also discusses the emotional component of living with chronic illness and the importance of self-advocacy and tailoring treatment to individual needs. Tina talks about: - 4 things I wish I knew sooner about living with ulcerative colitis - How diet really affects ulcerative colitis: what worked (and what didn't) for me - Medications and UC: what helped, what didn't, and what I learned - The emotional side of ulcerative colitis: navigating stress, shame, and uncertainty Connect with Tina Haupert: https://carrotsncake.com/ Facebook: Carrots 'N' Cake https://www.facebook.com/carrotsncake Instagram: carrotsncake https://www.instagram.com/carrotsncake YouTube: Tina Haupert https://www.youtube.com/user/carrotsncake Pinterest: Carrots 'N' Cake Hormone Testing & Nutrition Coaching https://www.pinterest.com/carrotsncake/ About Tina Haupert: Tina Haupert is the owner of Carrots ‘N' Cake as well as a Certified Nutrition Coach and Functional Diagnostic Nutrition Practitioner (FDN-P). Tina and her team use functional testing and a personalized approach to nutrition to help women find balance within their diets while achieving their body composition goals.

Send us a textSarah sits down with Addiction Medicine expert Dr. Carolyn Chan on this latest episode. Dr. Chan has great tips and tricks for how to care for patients with substance use disorders (SUD) inpatient and outpatient. No matter what kind of provider you will be, SUD will be a part of your patients' lives! Look out for the discussion on RIP TEAR and how you can approach every patient encounter involving substance use disorders with confidence and respect. Dr. Chan has her own podcast, @The Curbsiders Addiction Medicine! Take a listen to their great talks too! UC's Hoxworth Addiction Recovery Clinic: https://med12.uc.edu/depart/intmed/residency/internal-medicine/the-way-we-learn/resiliency

After being turned down by Brent to go to prom, Lola decides to throw a prom of her own.The Loved Ones is an excellent movie that is both brutal and comedic and it continues to get more sadistic as the film goes on. It focuses on themes of loneliness, acceptance, and grief and ties up all loose ends by the end for a full depiction of the character motivations. The movie also tosses in a few twists that make the movie such a fun watch. The Loved Ones was a surprise and one that we've gone back to a few times to rewatch. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Dr. Bill Davis and Tony Hook on the UCM Podcast.  Feeling overwhelmed and out of bandwidth in your UC practice—but still haven't hired help? You're not alone. In this episode, Dr. Bill Davis and Tony Hook break down why hiring associates feels so hard, the 5 reasons UC docs stay solo, and how to finally fix it with a proven system. Whether it's your first hire or your fourth, this conversation gives you clarity, confidence, and a game plan. What You'll Learn: ·        Why traditional hiring methods don't work for UC practices ·        The top 5 reasons docs avoid hiring—even when they're ready ·        How the multi-doctor model unlocks scalability and freedom ·        How to know if your practice is truly ready ·        A look inside UCM's Done-for-You Associate Recruitment Program

Cultural Enclaves, Movies & Politics, Kind Strangers, and more! エスニックエンクレイブ、映画と政治、優しい他人など！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

On today's episode of the Cops and Writers Podcast, I have with me, Author and Retired DEA Special Agent Léo Silva, for this special two-part interview that will conclude next Sunday.Leo Silva spent over twenty-eight years on the frontline of the global war on drugs as a special agent with the DEA. Leo's journey took him from the alleyways of Fronton Street to some of the most dangerous corners of North America, leading high-impact investigations against the Zeta and Gulf Cartels.He served as the Resident Agent in Charge of the DEA's Monterrey office, overseeing complex, cross-border operations that resulted in hundreds of high-value arrests and multi-million-dollar asset seizures. Over the course of his decorated career, he also held leadership roles in McAllen, Texas, and Guadalajara, Mexico—pioneering collaborative missions with Mexican authorities and helping rewrite the playbook for modern narco enforcement.Now, Leo has turned his attention to storytelling. His debut memoir, Reign of Terror, offers a powerful, unfiltered look at the reality behind the headlines—a world of corruption, courage, and the personal cost of justice. The book has gained traction internationally and has been translated into Spanish for a Latin American release.Leo is the real deal. This is a guy who has worked undercover numerous times in America and went after some of the most dangerous Mexican drug cartels. Please enjoy my chat with Leo Silva. In today's episode we discuss:· I would like to thank Chris Feistl for setting up this intro. If you'd like to check out my interview with Chris, a retired DEA agent with a compelling story to share, head over to episodes 217 and 218.· How he got interested in a career with the DEA.· How playing golf in high school helped his future career in the DEA.· Serving mobsters in a restaurant where he worked as a kid.· Being a full-time musician before joining the DEA.· You were one of the only Spanish speakers when you were an agent in Texas?· Being a new DEA agent and going undercover buying heroin.· How he kept his sanity and your identity while doing UC work.· Some of the scariest moments as an undercover agent?· Going to work in Mexico as a DEA agent attempting to shut down ruthless drug cartels.· His relationship with the often corrupt Mexican police and how difficult it was to extradite criminals.All of this and more on today's episode of the Cops and Writers podcast.Head on over to Leo's website to learn more about him and his work.Check out the new Cops and Writers YouTube channel!Check out my newest book, The Good Collar (Michael Quinn Vigilante Justice Series Book 1)!!!!!Enjoy the Cops and Writers book series.Please visit the Cops and Writers website.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textMarch 14 UC 0088. The New Desides fleet battles the Task Force Alpha to decide the fate of Ayers City.  The FAZZ squadron faces Cod in the Gundam Mk V, while the Xeku Zwei also makes its debut. Roots prepares to face the New Desides in S Gundam's most powerful form; the Ex-S Gundam.Gundam Sentinel Podcast/Gundam Book Club is performing a critical analysis and commentary and is protected by the Fair Use clause of the United States Copyright law. Gundam content is copyright and/or trademark of Sunrise Inc., Bandai, Sotsu Agency, or its original creator.  Gundam Sentinel content is copyright and/or trademark of Model Graphix, or its original creator.  Gundam Sentinel Podcast/Gundam Book Club is in no way affiliated with or endorsed by Sunrise, Bandai, Sotsu, Model Graphix or any of their subsidiaries, employees, or associates and makes no claim to own Gundam or any of the copyrights or trademarks related to it. Copyrighted content used in Gundam Sentinel Podcast/Gundam Book Club is used in accordance with the Fair Use clause of the United States Copyright law. Music used in this episode is being used under the "Fair Use" clause.  Please email gundamsentinelpodcast@gmail.com with any questions.Reference:https://www.nasa.gov/mission_pages/apollo/missions/apollo11.htmlhttps://en.wikipedia.org/wiki/We_choose_to_go_to_the_Moonhttps://en.wikipedia.org/wiki/Apollo_11https://en.wikipedia.org/wiki/Tranquility_BaseModel Graphix Special Edition "Gundam Wars III" - Gundam Sentinel The Battle of "Real Gundam".

Recent Iowa Weather Highlights Heavy Rainfall: Rain gauges in the Des Moines area report 1–2.2 inches; some areas in western/central Iowa received up to 6 inches in the past week. Southeast Iowa remains much drier, with some locations getting less than 0.1 inch.   Historical Context: July 11, 1993: Major flooding in Des Moines, with 250,000 residents losing water after levee breaches. 1993 marked 20 out of 37 consecutive days of measurable rain somewhere in Iowa. Current Wet Stretch: Statewide rainfall is 137% of normal for July so far. Several stations have received half a month's rainfall in just the last 10 days. Dew points remain high (60s–70s), signaling ongoing Gulf moisture. Weather Outlook Short-Term Forecast: Active weather continues for the next two days, with a chance of severe storms (supercells transitioning to linear systems). Flood warnings and flash flood watches remain in effect. After the weekend, temperatures return to the 90s, then cool down. Medium & Long-Term Outlook: July 16–20: Likely below-normal temperatures, leaning wet. July 18–24: Continued cool and wet trend. End of July: Warmer temperatures expected, with equal chances for precipitation. Southeast Iowa may remain drier than other regions. Regional Details: The "blue bullseye" for cooler weather covers eastern Nebraska, most of Iowa, Minnesota, and Wisconsin. Weather Patterns & Impacts Storm Dynamics: Stationary fronts and ample Gulf moisture are causing repeated thunderstorms. Linear wind profiles have led to more squall lines and fewer tornadoes. "Training" thunderstorms have produced localized heavy rain. Precipitation Trends: 40% of Iowa's annual precipitation typically falls on just 10 days. High-intensity, short-duration rain events are becoming more common, often leading to localized flooding and drought in different parts of the state. National Weather Note: Texas Flooding Recent Event: Two Texas locations received 11 inches of rain in just over 24 hours. Catastrophic flooding on the Guadalupe River, with water rising 20–30 feet in under an hour. Factors: Gulf and monsoonal moisture, remnants of Tropical Storm Barry, and stalled weather systems. Similar patterns have caused flash flooding in Iowa (e.g., Clive in 2018, Des Moines metro in 2019). Specialty Crop & Pest Updates Disease Risks: Continued wetness raises concerns about foliar diseases (e.g., black rot in brassicas and cabbage). Wet conditions and heavy dews may increase disease pressure as the season progresses. Pest Observations & Management: Japanese Beetles: Active on crops like zinnias, basil, and sweet corn (can affect pollination if silk is heavily clipped). Control options: Conventional sprays (e.g., Mustang Maxx), manual removal, and using trap crops. Colorado Potato Beetle: Reports of spinosad resistance. Alternative controls: Physical removal (bucket method), azadirachtin, or biological products (though some, like certain BT strains, are hard to find). Potatoes can tolerate 33% defoliation before yield loss. Onion Thrips: High populations observed in some fields, causing silvery-white damage. Economic thresholds vary (1–3 thrips/leaf per Cornell/UMass; up to 30 per UC). Control: Multiple modes of action, increased spray volume, horticultural oils, azadirachtin, and soil treatments with fungi or nematodes. Other Notes & Events Field Days & Workshops: August 2: Field day at Grow Johnson County's Poor Farm, covering no-till vegetable research and a short food safety workshop (counts as an annual update for PSA-trained growers). Agrivoltaic field days in Ames: Ongoing research on crops grown under solar panels, with field days every other week through September. Podcast summary generated using perplexity.ai

En la edición de Los Tenores de este jueves 10 de julio, nuestros panelistas analizaron las jornadas de entrenamiento de la Universidad de Chile y Colo Colo, de cara al Superclásico del sábado. Rodrigo Hernández, Pamela Juanita Cordero, Francisco Mouat, Patricio Barrera y Carlos Costas escucharon la conferencia de capitanes de albos y azules en la sede de la ANFP, donde Esteban Pavez y Marcelo Díaz fueron los encargados de responder. Además, comentaron las medidas de seguridad que se están implementando para la realización del partido en el Nacional. También conocieron las fechas tentativas para realizar la aplazada Supercopa. Revive la edición de Los Tenores de este jueves 10 de julio y no te pierdas ningún detalle del “clásico de las 2”, donde también supieron del optimista presente en la UC y, al cierre, hubo espacio para una nueva versión del “11 de Manolo”, referente a los rostros de TV.See omnystudio.com/listener for privacy information.

Tony talks foot injuries with Bob Mangine from UC and NovaCare on ESPN 1530!

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

In this conversation, Keltie Maguire speaks with shawdeez, Ph.D. (he/they), a queer and trans parent, about their journey to parenthood and the transformative experiences that awaited them on the other side of having a child.  shawndeez shares... The impact of societal gender norms, both on shawndeez's feelings about parenthood and in how these norms can influence anyone making this decision. shawndeez's experience navigating the IVF process as a transmasculine person. The importance of creating a gender-open environment for children that fosters freedom and exploration. The spiritual awakening that can accompany parenthood, and insights into shawndeez's own spiritual journey through parenthood. The significance of connecting with nature, and the pursuit of joy and bliss in parenting. Self-worth and the need to challenge traditional narratives around family and identity. As mentioned in the show: Find shawndeez online at: shawndeez.com Find shawndeez on Instagram: instagram.com/drshawndeez/ About shawndeez: shawndeez, Ph.D. (he/they) received their doctorate in UCLA's Department of Gender Studies. While at UCLA, they created and led courses on Trans Magic, Queer & Trans Muslim Feminisms, and QTPoC Resistances while simultaneously serving on the Trans Wellness Team, a collective of medical doctors and mental health providers working to provide gender-affirming healthcare to trans students across the UC system. shawndeez's dissertation research explored how queer, trans, and nonbinary individuals engage with the spiritual as a form of resilience, healing, and possibility. They are now a full time public speaker, spiritual guide, and workshop facilitator, offering spiritually-conscious spaces for queer/trans people to lean into their joys. (I can tweak if needed, let me know). _ Get details on 1-on-1 coaching here: kidsorchildfree.com/coaching Check out our free resources here, or at kidsorchildfree.com/free-resources And don't forget to subscribe, rate, and review The Kids or Childfree Podcast if you love what you're hearing! You can leave a rating and review on Apple Podcasts, or a rating on Spotify. Find us online at www.kidsorchildfree.com. Instagram: www.instagram.com/kidsorchildfree

Tony talks with former UC Quarterback Dustin Grutza about UC athletics and today's college sports landscape on ESPN 1530!

The trade deadline is irrelevant right now. But when it is, will the Reds be willing to outbid? Plus, another Hunter Greene injury setback and Mo chat's with UC tight end Joe Royer, Offensive lineman Gavin Gerhardt and UC's athletic director from Big 12 media day.

UC's Athletic Director John Cunningham live from Big 12 Media Day

UC's Gavin Gerhardt from Big 12 media day

UC tight end Joe Royer live from Big 12 media day

UC's Gavin Gerhardt from Big 12 media day

UC tight end Joe Royer live from Big 12 media day

UC's Athletic Director John Cunningham live from Big 12 Media Day

It's a 7-7 portal activation day, full moon week and it's that time to see what the Runes have for us to help wake up our intuition and receive guidance Sign up for your own personal reading or attend my next in person transformational experience at www.MagdalenaGrace.com     FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS Our Women's Retreat is 9/9 - Build your business and life like a Queen Our Coed retreat is Oct 17-19th BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.SanDiegoKambo.com  www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q   

A grieving mother-daughter relationship takes a turn for the worst, when young Leah performs a ritual in the woods to murder her mother.Pyewacket is a folk horror film that explores a family experiencing tragedy and a mother and daughter finding ways to cope and live with each other. While this movie covers the extreme ways of a young rebellious teenage girl copes with grief, the film does a good job of exploring grief and regret using folk horror as the genre. Many of the actions in the movie are quick, completely avoidable, and rash, but that's what makes it work as a coming-of-age movie. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Japanese Surnames, Bike Accident, US Politics, and more! 夫婦別姓、自転車事故、アメリカの政治など！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

The standard treatment for muscle-invasive urothelial carcinoma (MIUC) has been radical surgery combined with cisplatin-based chemotherapy for eligible patients. However, over 50% of patients face metastatic progression after surgery. This non-CME webinar, presented by a urology expert, will discuss how patients with UC at high risk of recurrence after radical resection may benefit from adjuvant immunotherapy, emphasize the role of multidisciplinary communication in patient care, and review a subcutaneous immunotherapy option for the adjuvant treatment of UC.

Send us a textI turned 35 yesterday. And this year, the birthday didn't feel like a celebration, it felt like a confrontation.Because for most of my 20s and early 30s, I told myself I could figure it out alone. And all it got me was burnout, shame, and a body that felt completely out of sync with the life I'd built.This episode is different.It's not a list of tips. It's the full story of how I went from ending up in the ER from ulcerative colitis and metabolic damage… to leading from the front as a corporate professional, coach, husband, and soon to be father, who finally feels like the man I'm supposed to be.Inside, I'll walk you through:The breaking point that shattered my prideWhat I learned from 3 different coaches (and what I'll never do to my own clients)The system I built from my pain, my profession, and my truthWhy I still use that same system to this day, while working a 9–5, managing my UC, and building a business.If you're done winging it. If your reflection doesn't match the man you are at work. If you know it's time to stop guessing...DM me “DESIGN” on Instagram.Let's build your system.If this episode hit home, make sure you're subscribed. This is Fitness by Design, the podcast for high-performing men ready to stop winging it and start leading with their body. For more stories, strategies, and hard truths: Follow me on Instagram – @spencerhgallo Connect with me on LinkedIn – Spencer Gallo Or shoot me a text, I read every single one. Let's keep building your edge, one episode at a time.

Watch on YouTube.In this jam-packed episode of UC Big News, host Kieran Devlin is joined by expert analysts Jon Arnold, Melody Brue, Craig Durr, and Zeus Kerravala for a whirlwind tour of the latest from the unified communications world.The team unpacks Mitel's return from bankruptcy, gets hands-on with Google Beam's volumetric video marvel, and decodes Cisco's new enterprise-focused vision for Webex, fresh from Cisco Live 2025.Whether you're a tech leader, vendor watcher, or just UC-curious, this is the episode to watch. Three seismic updates, one expert panel, here's what you'll learn in this episode:Mitel is back! The team debates whether slashing $1.15 billion in debt and doubling down on hybrid UC is enough to revive the brand in a cloud-first world.Google Beam wowed InfoComm — with light field displays, spatial audio, and real-time translation. Melody Brue calls it “shockingly natural,” while the crew unpacks pricing, practicality, and use cases from executive comms to telehealth.Cisco pivots Webex — unveiling a security- and observability-first pitch at Cisco Live. Is this a necessary evolution for serious enterprise buyers? The team weighs in on whether this is Cisco's best Webex strategy yet.Big questions raised — from the future of on-prem UC to whether 3D meeting rooms can scale, and if Cisco's security-first focus can win back market momentum.Next Steps: ✅ Subscribe to UC Big News for sharp, unscripted insights on UC, CX, and collaboration.

Oof, what a stacked show this week: Germany's minimum wage saga reaches its disappointing denouement, German voters begin to wonder what the SPD is actually for, and Germany's Retail Institute comes up with an all but useless report on shoplifting. Meanwhile, a bold wood pigeon wants in on the mega sesh, and yes, wine and lemonade does indeed make an excellent summer drink. Salud!Megan's Megacan theme song by Eden Ottignon from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Planet OTT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy us a round, ask us a question! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Or follow us on whichever psychotic billionaire's data-fracking machine you like best:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/MegansMegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC-o_U5nqe4_-yKfOm1CXOPA⁠⁠⁠⁠⁠

Send us a textMarch 13 UC 0088. The Bald Eagle enters the battlefield and faces his former student. The New Desides and their complement of mobile suits fiercely battle the Task Force Alpha. Also… A.L.I.C.E. becomes more aware.Notebook LLM ironically tackles the use of AI and sabotaging military and government assets, and talks about Battlestar Galactica (reboot).Gundam Sentinel Podcast/Gundam Book Club is performing a critical analysis and commentary and is protected by the Fair Use clause of the United States Copyright law. Gundam content is copyright and/or trademark of Sunrise Inc., Bandai, Sotsu Agency, or its original creator.  Gundam Sentinel content is copyright and/or trademark of Model Graphix, or its original creator.  Gundam Sentinel Podcast/Gundam Book Club is in no way affiliated with or endorsed by Sunrise, Bandai, Sotsu, Model Graphix or any of their subsidiaries, employees, or associates and makes no claim to own Gundam or any of the copyrights or trademarks related to it. Copyrighted content used in Gundam Sentinel Podcast/Gundam Book Club is used in accordance with the Fair Use clause of the United States Copyright law. Music used in this episode is being used under the "Fair Use" clause.  Please email gundamsentinelpodcast@gmail.com with any questions. Reference:https://en.wikipedia.org/wiki/Battlestar_Galactica_(2004_TV_series)https://en.wikipedia.org/wiki/Cyberwarfare_in_the_United_Stateshttps://en.wikipedia.org/wiki/Logic_bombModel Graphix Special Edition "Gundam Wars III" - Gundam Sentinel The Battle of "Real Gundam".

Please visit answersincme.com/WHF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss how the latest therapeutic advances in frontline management of urothelial carcinoma can be integrated into practice to optimize patient care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the first-line treatment of advanced UC; Identify multidisciplinary strategies to optimize first-line treatment of patients with advanced UC; and Outline current and evolving multidisciplinary approaches to enhance outcomes for patients with UC.

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

In this episode, Dr. Andy Cutler and Dr. Jeffrey Strawn explore the complexities of obsessive-compulsive disorder (OCD). Join the conversation as they discuss how OCD presents across different patients, evidence-based treatment approaches, and the critical role clinicians play in helping individuals manage symptoms and work toward remission.  Jeffrey R. Strawn, MD, FAACAP is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

Send us a textNavigating the workplace while managing inflammatory bowel disease can feel like walking a tightrope—balancing health needs against career responsibilities. This episode cuts through the confusion with straightforward, practical advice from someone who truly understands both sides of the equation.Employment attorney Abbe Feitelberg returns to share her unique perspective as both an IBD patient and legal expert. She breaks down the Family Medical Leave Act (FMLA) and Americans with Disabilities Act (ADA) in clear, accessible terms that empower you to advocate for yourself in any workplace situation. From understanding which companies must comply with these laws to learning exactly what paperwork you need, Abbe demystifies the process of securing your workplace rights.The conversation explores common misconceptions, like believing managers need detailed medical information (they don't!) or that requesting accommodations might hurt your career (it shouldn't!). You'll discover practical strategies for maintaining privacy while getting the support you need, whether that's intermittent leave for treatments, flexible scheduling during flares, or immediate bathroom access. Most importantly, you'll learn how to document everything properly to protect yourself if issues arise.What makes this episode particularly valuable is how it addresses real-world scenarios: When should you disclose your condition? What happens if your accommodation request is denied? How do you balance transparency with privacy? As Abbe points out, "These protections exist to help you succeed—never be afraid to ask for what you need." Whether you're currently employed, job hunting, or supporting someone with IBD, this episode provides crucial knowledge to navigate workplace challenges with confidence and dignity.Links: Abbe's first episode with usUS Equal Employment Opportunity CommissionInfo on the Americans with Disabilities ActInfo on the Family Medical Leave ActEmployee and Employer resources- Crohn's & Colitis Foundation- USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Tony and Austin talk about a little bit of everything. From the Reds, to in-game entertainment, to the new UC uniforms, to Mo Egger and more on ESPN 1530!

Today on the Show: We'll feature an extended interview with United Farm Workers President, Teresa Romero, speaking out against the crackdown on those brown workers who do the hardest work in this country and now face jail and deportation for their amazing and crucial efforts. Romero was arrested recently during a UCSF Reagent's meeting in San Francisco to express total solidarity with UC frontline workers. Also, Renee Saucedo, founder of ALMAS Libres/Raizes Collective joins us for a report on the Trump crackdown on domestic workers and day laborers. And Mike Fernera, past national director of Veterans For Peace,threw blood on the U.S. mission in New York and sai The post United Farm Workers President, Teresa Romero Speaks Out Against Trumps Racist Deportation Crackdown appeared first on KPFA.

Runes reading for week of June 30th - FREEDOM week Tune in to plan your week accordingly  SIGN UP FOR THIS WEEKEND'S FREEDOM WEEKEND WORKSHOP OR OTHER EVENTS AT www.MagdalenaGrace.com   FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?        SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q  Sign up for a personal reading at www.MagdalenaGrace.com  

Charlie suspects his new neighbor of being a vampire and turns to an unlikely source for help in the form of a washed-up actor who portrays a vampire hunter on a television show.Fright Night is the finale of Retro Reel 2025 as it should. This movie is always a joy to watch from the memorable set of characters to the tense dialogue, it constantly picks up the pace. We were particularly impressed with the performances of Chris Sarandon as Jerry Dandrige and Roddy McDowall as Peter Vincent. While keeping some old vampire tropes, this film does add original elements and the portrayal of the vampires is hideous in the most amazing way possible. With great practical effects, excellent soundtrack, and an engaging story, Fright Night is a super fun experience. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!

Mental Health, Marathon Training, Political Apathy, and more! メンタルヘルス、マラソントレーニング、政治的無関心など！ Join our Discord: https://discord.gg/VGSd94Tp4P Join our Book Club! https://ko-fi.com/i/IF1F01EWI60 Support on ko-fi:  https://ko-fi.com/lazyfluency Main channel:  https://www.youtube.com/channel/UC-8_djC5_aV4Mi3o3fuLPLA Send us questions at:  lazyfluency@gmail.com  

Amanda is from Colerain and is a Teacher Assistant that works with special education. She's a Mom of 4 and her oldest just graduated is heading to UC this Fall. She says she listens everyday and B-105 always puts her in a good mood! To make her induction complete, Amanda wanted to hear "Chasin' You" by Morgan Wallen so she could tap that track for another chance to see Morgan in Miami! Welcome to the B-105 Country Club, Amanda!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

More Germans can't live on their wages, but the new minimum wage commission has decided to raise it, erm, minimally — ensuring another neoliberal wet dream this weekend for BlackRock Chancellor Friedrich Merz. Meanwhile, Olaf Scholz gets a shiny new office (but what for?), the Bundestag president is unnecessarily mean to the LGBTQ community, and we can confirm that former Health Minister Jens Spahn is indeed a wanker. All in a day's work for the Megacanners. Cheers!Megan's Megacan theme song by Eden Ottignon from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Planet OTT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy us a round, ask us a question! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Or follow us on whichever psychotic billionaire's data-fracking machine you like best:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/megansmegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/MegansMegacan⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC-o_U5nqe4_-yKfOm1CXOPA⁠⁠⁠⁠⁠

SUBSCRIBE to The One to Go Show presented by ImpactHealth SharingSoil & Ag Solutions- https://www.agconcepts.com/  320-219-3542Fast Lane Motorsports and powdercoating- http://www.fastlanemotorsports.orgEastCentral Sports- http://www.eastcentralsports.comFB- https://www.facebook.com/OnetoGoShowSpotify: https://open.spotify.com/episode/4fO19zPyhuwqb74Ut3jgho?si=clWSn-DVQkmp8W_f95p4IgTikTok- @theonetogoshowSnapchat-@theonetogoshowRumble:  https://rumble.com/v57phvx-71524-the-one-to-go-show-presented-by-impact-health-sharing.htmlYouTube: https://www.youtube.com/channel/UC_r_TSMx2XEfMfJ9Vc1ez0w?view_as=subscriberWe'd like to hear from you: theonetogoshow@gmail.comA productionof G.O.A.T. Sports Media LLC

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Wednesday, June 25th, 2025Today, former DoJ lawyer Erez Reuveni issues a bombshell whistleblower account of Emil Bove's intentional defiance of court orders on the eve of his judicial confirmation hearing; US intelligence assessments indicate that Iran's nuclear sites were not destroyed and they can be back up and running in a few months; Florida is paving over the Everglades to build its own concentration camp; a federal judge has blocked Trump's termination of University of California research grants; the Senate parliamentarian nixes the public lands selloff in the Billionaire Bailout Bill; four tech execs are sworn in as lieutenant colonels in the Army; Senator Lisa Murkowski signals she may turn Independent and caucus with Democrats; House Dems choose youth over seniority in the House Oversight ranking member election; and Allison delivers your Good News.Thank You, DeleteMeGet 20% off your DeleteMe plan when you go to joindeleteme.com/DAILYBEANS and use promo code DAILYBEANS at checkout. Thank You, Daily LookFor 50% off your order, head to DailyLook.com and use code DAILYBEANS. Thank You, CBDistilleryUse promo code DAILYBEANS at CBDistillery.com for 25% off your purchase.  Specific product availability depends on individual state regulations.Check out Dana's social media campaign highlighting LGBTQ+ heroes every day during Pride Month -  Dana Goldberg (@dgcomedy.bsky.social)Guest: Martha BarnetteFriends with Words Adventures in Languageland - book by Martha BarnetteMarthaBarnette.comA Way with Words Podcast@marthabarnette - BlueSky, Martha Barnette (@martha.barnette) - Instagram, MarthaBarnette - twitterStoriesStrike Set Back Iran's Nuclear Program by Only a Few Months, U.S. Report Says | The New York TimesLive updates: Trump lashes out at Israel and Iran amid accusations of ceasefire violations | NBC NewsWhat Big Tech's Band of Execs Will Do in the Army | WIREDFlorida Builds ‘Alligator Alcatraz' Detention Center for Migrants in Everglades | The New York TimesHouse Democrats Elect Robert Garcia for Top Oversight Post | The New York TimesJudge blocks Trump's termination of UC research grants | Courthouse News ServiceMurkowski suggests she could become an Independent in the right circumstance - Live Updates | POLITICOGOP budget bill could threaten public lands, conservation groups voice opposition | NBC MontanaFrom The Good Newsuncomplicatedkitchen.org'No Kings' Protests see thousands in San Antonio area speak out, joining national movementGay Men's Chorus Of Washington, DCPotomac Fever (@potomac.fever) -  Instagram‘Get ready to sweat!' The animal mega-marathon stampeding from the Congo to the Arctic | Stage | The GuardianBe Biscuit's Hero - AZ Humane SocietyStar 67 - The Daily Beans - Apple PodcastsReminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! patreon.com/muellershewrote Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good TroubleMSW Good News and Good Trouble Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, BlueSky|@muellershewrote , Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWrote,Dana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

At the time of this recording, we are preparing to head into 4th of July in just over one week which is a holiday all about freedom How do YOU define freedom? Let's talk about that today and how you can find/create more freedom in your life! FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.SanDiegoKambo.com  www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q   

Workers Against Ice Petition: Oakland Children's Hospital Strike Fund: After a brief detour discussing the necessity for labor to unite against the US-Israeli war on Iran, we dive into our regular labor headlines. This week we've got followups with striking grocery workers, beverage distribution workers, tabletop game store employees, teachers, and farmworkers. Our first story returns to one of the more horrific forms of labor in this country, prison slavery, as incarcerated workers in Alabama fight to just have the state follow its own laws. Next, gig workers in India are facing dystopian new conditions of ten minute worker deliveries. Research assistants at the University of Illinois Urbana-Champaign are on the verge of forming one of the largest single campus grad unions in the country. Finally, healthcare workers at Oakland Children's Hospital are on strike after their employers in the UC system are proposing to slash their benefits. Join the discord: discord.gg/tDvmNzX  Follow the pod at instagram.com/workstoppage, @WorkStoppagePod on Twitter,  John @facebookvillain, and Lina @solidaritybee

Another HUGE week (I feel like I say that every week!) in the energies A new moon is upon us and it's time to set intentions in health, wealth and relationships with Magical Mags Runes reading and ritual The New Moon in Cancer in 2025 will occur on June 25th at 3:31 am PT. This New Moon is happening during Cancer season, which is a time for focusing on home, family, and emotional renewal. It's a time to connect with your emotions, nurture yourself, and explore new definitions of home Jupiter is also conjunct the sun for EXPANSION AND POTENCY on steroids Tune in to the divination reading and see what  comes thru for YOU What intentions will you set? Bring a journal 1:30 inhalation and grounding 2:55 current astrology 8:29 announcements of transformational webinar and workshop 9:58 runes pull/reading 19:25 animal medicine card pull 23:00 runes singing/intonation 26:35  write out your new moon in cancer sacred intention for health/wealth or relationships 29:00 donations for my suicide and mental health awareness scholarships   Hire her for your own personal 1-1 reading at www.MagdalenaGrace.com   FIND OUT MORE ABOUT MAGDALENA GRACE HERE or TO SIGN UP FOR HER UPCOMING ABUNDANCE ALCHEMIST IN PERSON WORKSHOPS OR HEALTHY N WEALTHY N WISE RETREATS BOOK A RUNES READING AND SIGN UP FOR HER WORKSHOPS & MORE! www.MagdalenaGrace.com   JOIN OUR HEALTHY N WEALTHY N WISE ONLINE ACADEMY  www.microdosingforhealth.com    BUY ME A COFFEE OR DONATE FOR SCHOLARSHIP FUND FOR HEALING CLIENTS IN NEED https://venmo.com/u/lotusthrone   MORE ALCHEMY OPPORTUNITIES FOR YOUR BEST HEALTH, WEALTH AND RELATIONSHIPS www.SanDiegoKambo.com  www.KundaliniFallbrook.com  www.LotusThroneSanctuary.com   WANNA SIGN UP AND BE A PLEDGING PATRON FOR HEALTHY N WEALTHY N WISE - SAVING LIVES AND CREATING MORE ABUNDANCE FOR OTHERS?  https://patron.podbean.com/magdalena     SUBSCRIBE TO HER YOUTUBE CHANNEL: https://www.youtube.com/@UC_l0t_6TBbZ1q9Q0wKZz89Q 

The legend in the small, coastal town of Antonio Bay is of a ship lured to the land and swallowed up by a mysterious thick cloud as it sank. The locals say when the fog returns, the dead will arise from their watery graves.The Fog, directed by John Carpenter, fits quite nicely into Retro Reel 2025. It stars horror greats such as Adrienne Barbeau, Jamie Lee Curtis, Tom Atkins, and Hal Holbrook and like most Carpenter films, features an electric soundtrack. The film gives off eerie vibes and has multiple character stories that are bridged together quite nicely as the secrets of Antonio Bay are revealed throughout the movie. While the film is not without its flaws, it's fun to watch a mystery, ghost story, and revenge plot all wrapped into one. Watch the movie and catch our review.Subscribe to our YouTube channel @thefinalpodcast  Join the Discord | https://discord.gg/UFtVP243Follow us on Facebook The Final Podcast Follow us on Instagram @thefinalpodcastFollow us on X @thefinalpodeverMusic Credit: Karl Casey @ White Bat Audiohttps://www.youtube.com/channel/UC_6h...What should we review next? Toss us a vibe and send over a recommendation!